Ivan Monteleone

Summary

Affiliation: University of Rome Tor Vergata
Country: Italy

Publications

  1. ncbi Aryl hydrocarbon receptor-induced signals up-regulate IL-22 production and inhibit inflammation in the gastrointestinal tract
    Ivan Monteleone
    Dipartimento di Medicina Interna, Universita Tor Vergata, Rome, Italy
    Gastroenterology 141:237-48, 248.e1. 2011
  2. ncbi Interleukin-21 enhances T-helper cell type I signaling and interferon-gamma production in Crohn's disease
    Giovanni Monteleone
    Dipartimento di Medicina Interna e Centro di Eccellenza per lo studio delle malattie complesse e multifattoriali, Universita Tor Vergata, Rome, Italy
    Gastroenterology 128:687-94. 2005
  3. ncbi Interferon-gamma-expressing cells are a major source of interleukin-21 in inflammatory bowel diseases
    Massimiliano Sarra
    Department of Internal Medicine, University of Rome Tor Vergata, Rome, Italy
    Inflamm Bowel Dis 16:1332-9. 2010
  4. ncbi Involvement of interleukin-21 in the regulation of colitis-associated colon cancer
    Carmine Stolfi
    Gastroenterology Unit, Department of Internal Medicine, University of Rome Tor Vergata, Rome, Italy
    J Exp Med 208:2279-90. 2011
  5. ncbi Inhibition of colitis by IL-25 associates with induction of alternatively activated macrophages
    Angelamaria Rizzo
    Department of Internal Medicine, University Tor Vergata of Rome, Rome, Italy
    Inflamm Bowel Dis 18:449-59. 2012
  6. ncbi Characterization of IL-17A-producing cells in celiac disease mucosa
    Ivan Monteleone
    Dipartimento di Medicina Interna, Universita Tor Vergata, Rome, Italy
    J Immunol 184:2211-8. 2010
  7. ncbi CARD15 mutation analysis in an Italian population: Leu1007fsinsC but neither Arg702Trp nor Gly908Arg mutations are associated with Crohn's disease
    Piero Vavassori
    Cattedra di Gastroenterologia, Centro d eccellenza per lo studio del rischio genomico in patologie complesse e multifattoriali, Universita Tor Vergata, Rome, Italy
    Inflamm Bowel Dis 10:116-21. 2004
  8. ncbi Post-transcriptional regulation of Smad7 in the gut of patients with inflammatory bowel disease
    Giovanni Monteleone
    Department of Internal Medicine and Centre of Excellence for Genomic Risk Assessment in Multifactorial and Complex Diseases, University of Tor Vergata, Rome, Italy
    Gastroenterology 129:1420-9. 2005
  9. ncbi A functional role of flip in conferring resistance of Crohn's disease lamina propria lymphocytes to FAS-mediated apoptosis
    Ivan Monteleone
    Dipartimento di Medicina Interna e Centro di Eccellenza per lo studio delle malattie complesse e multifattoriali, Universita Tor Vergata, Rome, Italy
    Gastroenterology 130:389-97. 2006
  10. ncbi 2-Methoxy-5-amino-N-hydroxybenzamide, a derivative of mesalamine, inhibits colon cancer cell growth through cyclo-oxygenase-2-dependent and -independent mechanisms
    Carmine Stolfi
    Department of Internal Medicine, University of Rome Tor Vergata, Rome, Italy
    Clin Sci (Lond) 123:295-306. 2012

Collaborators

Detail Information

Publications20

  1. ncbi Aryl hydrocarbon receptor-induced signals up-regulate IL-22 production and inhibit inflammation in the gastrointestinal tract
    Ivan Monteleone
    Dipartimento di Medicina Interna, Universita Tor Vergata, Rome, Italy
    Gastroenterology 141:237-48, 248.e1. 2011
    ..We investigated the role of AhR in inflammation and pathogenesis of IBD in humans and mouse models...
  2. ncbi Interleukin-21 enhances T-helper cell type I signaling and interferon-gamma production in Crohn's disease
    Giovanni Monteleone
    Dipartimento di Medicina Interna e Centro di Eccellenza per lo studio delle malattie complesse e multifattoriali, Universita Tor Vergata, Rome, Italy
    Gastroenterology 128:687-94. 2005
    ..In this study, we examined the expression and role of IL-21, a T-cell-derived cytokine of the IL-2 family; in tissues and cells isolated from patients with inflammatory bowel disease...
  3. ncbi Interferon-gamma-expressing cells are a major source of interleukin-21 in inflammatory bowel diseases
    Massimiliano Sarra
    Department of Internal Medicine, University of Rome Tor Vergata, Rome, Italy
    Inflamm Bowel Dis 16:1332-9. 2010
    ..However, the phenotype of IL-21-producing cells in IBD, and the cytokine(s) they coproduce, is not known. We here characterized the cell source of IL-21 and determined which factors regulate IL-21 in the human gut...
  4. ncbi Involvement of interleukin-21 in the regulation of colitis-associated colon cancer
    Carmine Stolfi
    Gastroenterology Unit, Department of Internal Medicine, University of Rome Tor Vergata, Rome, Italy
    J Exp Med 208:2279-90. 2011
    ..These observations indicate that IL-21 amplifies an inflammatory milieu that promotes CAC, and suggest that IL-21 blockade may be useful in reducing the risk of UC-associated colon cancer...
  5. ncbi Inhibition of colitis by IL-25 associates with induction of alternatively activated macrophages
    Angelamaria Rizzo
    Department of Internal Medicine, University Tor Vergata of Rome, Rome, Italy
    Inflamm Bowel Dis 18:449-59. 2012
    ..Since Th2-cytokines can abrogate inflammatory pathways by inducing alternatively activated macrophages (AAMs), we evaluated whether AAMs are involved in the IL-25-mediated anticolitic effect...
  6. ncbi Characterization of IL-17A-producing cells in celiac disease mucosa
    Ivan Monteleone
    Dipartimento di Medicina Interna, Universita Tor Vergata, Rome, Italy
    J Immunol 184:2211-8. 2010
    ..In conclusion, our data show that IL-17A is increased in CD and is produced by cells that also make IFN-gamma...
  7. ncbi CARD15 mutation analysis in an Italian population: Leu1007fsinsC but neither Arg702Trp nor Gly908Arg mutations are associated with Crohn's disease
    Piero Vavassori
    Cattedra di Gastroenterologia, Centro d eccellenza per lo studio del rischio genomico in patologie complesse e multifattoriali, Universita Tor Vergata, Rome, Italy
    Inflamm Bowel Dis 10:116-21. 2004
    ..The purpose of this study was to evaluate the frequency of the main mutations of the CARD15 gene (Leu 1007fsinsC, Arg702Trp, and Gly908Arg) in Italian CD patients and to establish possible genotype-phenotype correlations...
  8. ncbi Post-transcriptional regulation of Smad7 in the gut of patients with inflammatory bowel disease
    Giovanni Monteleone
    Department of Internal Medicine and Centre of Excellence for Genomic Risk Assessment in Multifactorial and Complex Diseases, University of Tor Vergata, Rome, Italy
    Gastroenterology 129:1420-9. 2005
    ..In this study, we examined the molecular mechanism underlying the induction of Smad7 in the human gut...
  9. ncbi A functional role of flip in conferring resistance of Crohn's disease lamina propria lymphocytes to FAS-mediated apoptosis
    Ivan Monteleone
    Dipartimento di Medicina Interna e Centro di Eccellenza per lo studio delle malattie complesse e multifattoriali, Universita Tor Vergata, Rome, Italy
    Gastroenterology 130:389-97. 2006
    ..In this study we examined the functional role of Flip, a Flice inhibitor protein, in the resistance of CD LPL to FAS-mediated apoptosis...
  10. ncbi 2-Methoxy-5-amino-N-hydroxybenzamide, a derivative of mesalamine, inhibits colon cancer cell growth through cyclo-oxygenase-2-dependent and -independent mechanisms
    Carmine Stolfi
    Department of Internal Medicine, University of Rome Tor Vergata, Rome, Italy
    Clin Sci (Lond) 123:295-306. 2012
    ..Taken together, these results suggest that 2-14 inhibits CRC cell growth through COX-2-dependent and -independent mechanisms...
  11. ncbi Inhibition of Smad7 with a specific antisense oligonucleotide facilitates TGF-beta1-mediated suppression of colitis
    Monica Boirivant
    Department of Infectious, Parasitic and Immune-mediated Diseases, Istituto Superiore di Sanit, Rome, Italy
    Gastroenterology 131:1786-98. 2006
    ..This may represent a new approach to the control of IBD, particularly during active phases when its Smad7 profile resembles that of hapten-induced colitis...
  12. ncbi Induction and regulation of Smad7 in the gastric mucosa of patients with Helicobacter pylori infection
    Giovanni Monteleone
    Department of Internal Medicine and Center for Excellence for Genomic Risk Assessment in Multifactorial and Complex Diseases, University Tor Vergata, Rome, Italy
    Gastroenterology 126:674-82. 2004
    ..Transforming growth factor (TGF)-beta 1 negatively regulates Th1 cell development, and TGF-beta 1-deficient mice spontaneously develop gastritis. Here, we examined TGF-beta 1 signaling in Hp-associated gastritis...
  13. ncbi 2-methoxy-5-amino-N-hydroxybenzamide sensitizes colon cancer cells to TRAIL-induced apoptosis by regulating death receptor 5 and survivin expression
    Carmine Stolfi
    Department of Internal Medicine, Universita Tor Vergata, Via Montpellier, 1 00133, Rome, Italy
    Mol Cancer Ther 10:1969-81. 2011
    ..These findings indicate that 2-14 acts as a sensitizer for TRAIL-induced apoptosis and suggest that 2-14 can be useful in the therapy for TRAIL-resistant colon cancer...
  14. ncbi The aryl hydrocarbon receptor in inflammatory bowel disease: linking the environment to disease pathogenesis
    Ivan Monteleone
    Department of Internal Medicine, University Tor Vergata of Rome, Rome, Italy
    Curr Opin Gastroenterol 28:310-3. 2012
    ..This review will summarize the current knowledge of the role of AhR in regulation of intestinal immune homeostasis and inflammation...
  15. ncbi Tissue inhibitor of metalloproteinase-3 regulates inflammation in human and mouse intestine
    Ivan Monteleone
    Dipartimento di Medicina dei Sistemi, Universita Tor Vergata, Rome, Italy
    Gastroenterology 143:1277-87.e1-4. 2012
    ..Tissue inhibitor of metalloproteinases (TIMP)-3 is an inhibitor of matrix metalloproteinases, which regulates tissue inflammation, damage, and repair. We investigated the role of TIMP-3 in intestinal inflammation in human beings and mice...
  16. ncbi Th17-related cytokines: new players in the control of chronic intestinal inflammation
    Ivan Monteleone
    Dipartimento di Medicina Interna, Universita Tor Vergata, Via Montpellier, Rome, Italy
    BMC Med 9:122. 2011
    ..These novel findings have contributed to advancing our understanding of mechanisms of gut tissue damage and open new avenues for development of therapeutic strategies in IBD...
  17. ncbi Genetic and pathogenetic insights into inflammatory bowel disease
    Francesco Pallone
    Cattedra di Gastroenterologia, Dipartimento di Medicina Interna, Universita Tor Vergata di Roma, Via Monpellier 1, 00133 Rome, Italy
    Curr Gastroenterol Rep 5:487-92. 2003
    ....
  18. ncbi Phase I clinical trial of Smad7 knockdown using antisense oligonucleotide in patients with active Crohn's disease
    Giovanni Monteleone
    Dipartimento di Medicina Interna, Universita Tor Vergata, Rome, Italy
    Mol Ther 20:870-6. 2012
    ..GED0301 treatment reduced the percentage of inflammatory cytokine-expressing CCR9-positive T cells in the blood. The study shows for the first time that GED0301 is safe and well tolerated in patients with active CD...
  19. ncbi Th17-cytokine blockers as a new approach for treating inflammatory bowel disease
    Ivan Monteleone
    Department of Internal Medicine, University Tor Vergata of Rome, Rome, Italy
    Ann Med 43:172-8. 2011
    ..In this article we review the available data supporting the pathogenic role of Th17 cytokines in IBD, and discuss whether and how inhibitors of these inflammatory mediators may enter into the therapeutic armamentarium of IBD...
  20. ncbi A failure of transforming growth factor-beta1 negative regulation maintains sustained NF-kappaB activation in gut inflammation
    Giovanni Monteleone
    Dipartimento di Medicina Interna e Centro di Eccellenza per lo studio delle malattie complesse e multifattoriali, Universita Tor Vergata, Rome 00133, Italy
    J Biol Chem 279:3925-32. 2004
    ..These data show that TGF-beta1 is a negative regulator of NF-kappaB activation in the gut and that Smad7 maintains high NF-kappaB activity in gut inflammation by blocking TGF-beta1 signaling...